BridgeBio Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BridgeBio Pharma, Inc.
Finance Watch: Biotech Valuations Seesaw On Bank Failure, Pharma M&A
Public Company Edition: The closure of Silicon Valley Bank sank biotech stocks in the first full week of March, but valuations rose the next week when two big acquisitions were announced. Also, J&J’s consumer health spinout sold $7.75bn in notes ahead of its future IPO and Karuna grossed $400m in a follow-on offering.
BridgeBio’s Achondroplasia Data Portend Competition With BioMarin’s Voxzogo
Already planning to position infigratinib as a safer, more convenient oral therapy for dwarfism compared with the BioMarin injectable, BridgeBio now has Phase II efficacy data showing a higher growth rate.
Rest In Peace SPACs And Pseudo-Platforms: What Lies Ahead For Biotechs Going Public In 2023
Panelists at the BIO CEO and Investor Conference foresee some changes coming as biotech investors become more judicious about where they park their money.
Finance Watch: Patient Square Capital Raises Mega-Fund, Topping Out At $3.9bn
Private Company Edition: Patient Square’s private equity fund, which surpassed its $3bn fundraising goal, may invest broadly across health care but the firm already has invested heavily in biopharma. Also, investor Dimension launches with a $350m specialized VC fund and Alto increased its series B to $60m.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Adrenas Therapeutics
- Aspa Therapeutics
- Audition Therapeutics
- Calcilytix Therapeutics
- CoA Therapeutics
- Fortify Therapeutics
- Origin Biosciences
- Phoenix Tissue Repair, Inc.
- QED Therapeutics
- Retinagenix LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.